Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases
The objective of this case series is to describe the efficacy and safety of baricitinib (BARI) in a group of patients with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA). These patients were treated with BARI due to either a refractory disease course or the unavailability of tociliz...
Saved in:
| Main Authors: | D. Camellino, C. Dejaco, F. Martini, R. Cosso, G. Bianchi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-10-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/reuma/article/view/1796 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01) -
18F-fluorodeoxyglucose positron emission tomography/ computed tomography of giant cell arteritis with lower extremity involvement in association with polymyalgia rheumatica
by: Ananya Panda, et al.
Published: (2021-03-01) -
Association of SSRI and SNRI use with incidence of cardiovascular events in veterans with giant cell arteritis and polymyalgia rheumatica
by: Tianyu Zhang, et al.
Published: (2025-04-01) -
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01) -
Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
by: Pierre-André Jarrot, et al.
Published: (2024-12-01)